Foreword on Moving Forward

Language about **identity**, **diversity**, **equity**, and **inclusion** evolves relatively quickly. The language and terms used throughout this course reflect contemporary best practice and guidance. To ensure continuous alignment with current best practice, terminology will be reviewed and updated as guidelines evolve. For example, when color is used regarding race, capital letters are used (e.g., Black, White, Brown), as recommended by the National Association of Black Journalists

CMEO
BriefCase

Advancing Health Equity Across the Spectrum

Optimizing Biomarker Usage in NSCLC

Supported by an educational grant provided by Johnson & Johnson.

This activity may include discussions of products or devices that are not currently labeled for use by the U.S. Food and Drug Administration (FDA).

The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Monica E. Peek, MD, MPH, MSc (Moderator)

Ellen H. Block Professor of Health Justice
Vice-Chair for Diversity, Equity and Inclusion
Department of Medicine
University of Chicago
Chicago, IL

Narjust Florez, MD, FASCO

Associate Director of The Cancer Care Equity Program
Co-Director, Young Lung Cancer Program
Thoracic Medical Oncologist, Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Boston, MA
Associate Editor, *JAMA Oncology*

CME OUTFITTERS

LEARNING OBJECTIVES

1. Identify social, economic, and clinician-driven factors that contribute to disparities in NSCLC biomarker testing and access to targeted therapy.

2. Integrate evidence-based strategies to reduce disparities by promoting timely, comprehensive biomarker testing for all eligible patients with NSCLC regardless of age, race, or socioeconomic status.

Significance of Biomarker Testing in NSCLC

- Biomarkers
  - **Prognostic** → indicative of patient survival independent of the treatment received, because the biomarker is an indicator of the innate tumor behavior
  - **Predictive** → indicative of therapeutic efficacy, because there is an interaction between the biomarker and therapy on patient outcome

Biomarker testing is crucial to therapy personalization and optimization and to estimate patient outcomes in NSCLC

NSCLC = non-small cell lung cancer.

National Comprehensive Cancer Network (NCCN). NCCN Website. 2025. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

Benefits of Biomarker Testing

- Improved survival outcomes
  - Targeted therapy selection based on biomarker testing significantly extends progression-free survival and overall response rate compared to traditional chemotherapy
  - Overall survival from real-world evidence
    - With molecular testing results, 28.8 months
    - Empirical therapy without molecular testing, 15.3-21.7 months
  - NCCN, ASCO, and ESMO emphasize broad-based molecular subtyping for patients with nonsquamous NSCLC
- Enhanced treatment precision
  - Actionable oncogenic drivers in ~55% of patients with advanced NSCLC
  - Improves the likelihood of receiving appropriate targeted treatments
- Operational and economic benefits
  - Reduces time from diagnosis to treatment initiation
  - NGS approaches demonstrate shorter turnaround times compared to sequential single-gene testing
  - All-cause health care costs during first-line therapy are similar between comprehensive and non-comprehensive genomic profiling

ASCO = American Society of Clinical Oncology; ESMO = European Society for Medical Oncology; NCCN = National Comprehensive Cancer Network; NGS = next-generation sequencing.

Sathiyapalan A, Ellis PM. *JCO Oncology Practice*. 2023;20(1):7-9. Scott JA, et al. *JCO Oncology Practice*. 2024;20(1):145-153. Šutić M, et al. *J Pers Med*. 2021;11(11):1102. Pennell NA, et al. *JCO Precis Oncol.* 2019;3:1-9. Tuminello S, et al. *J Natl Cancer Inst.* 2025;117(1):112-119.

Health Equity

- Biomarker testing significantly reduced risk of death
  - Black patients were less likely to receive biomarker testing than all other ethnicities
  - People living in areas with greater poverty had statistically significant decreased likelihood of molecular diagnostic testing
- Lower income, education, and lack of insurance limit access to advanced therapies such as immunotherapy and targeted therapy for NSCLC
- Rural populations have limited screening facilities, transportation difficulties, and higher percentages of uninsured individuals

Tuminello S, et al. *J Natl Cancer Inst.* 2025;117(1):112-119.
American Association for Cancer Research (AACR) Website. https://cancerprogressreport.aacr.org/disparities/.

Molecular Alterations in Lung Adenocarcinoma

- These alterations are predictive biomarkers for targeted therapies
- Additionally, PD-L1 is a predictive biomarker for immune checkpoint inhibitor therapies
- Tumor mutation burden



EGFR = epidermal growth factor receptor.

Šutić M, et al. *J Pers Med*. 2021;11(11):1102.
National Comprehensive Cancer Network (NCCN). NCCN Website. 2025. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.

Growing Repertoire of Targeted Therapies

Molecular and Biomarker-Directed Therapy for Advanced for Metastatic Disease

EGFR Exon 19 Deletion or Exon 21 L858R

- **First-line therapy**
  - Afatinib
  - Erlotinib
  - Dacomitinib
  - Gefitinib
  - Osimertinib
  - Osimertinib + pemetrexed + (cisplatin or carboplatin) (nonsquamous)
  - Erlotinib + ramucirumab
  - Erlotinib + bevacizumab (nonsquamous)
  - Amivantamab-vmjw + lazertinib
- **Subsequent therapy**
  - Osimertinib
  - Amivantamab-vmjw + carboplatin + pemetrexed (nonsquamous)
  - Datopotamab deruxtecan-dink (nonsquamous)

EGFR S7681, L861Q, and/or G719X

- **First-line therapy**
  - Afatinib
  - Erlotinib
  - Dacomitinib
  - Gefitinib
  - Osimertinib
- **Subsequent therapy**
  - Osimertinib

EGFR Exon 20 Insertion Mutation

- **First-line therapy**
  - Amivantamab-vmjw + carboplatin + pemetrexed (nonsquamous)
- **Subsequent therapy**
  - Amivantamab-vmjw
  - Sunvozertinib

KRAS G12C Mutation

- **Subsequent therapy**
  - Sotorasib
  - Adagrasib

ALK Rearrangement

- **First-line therapy**
  - Alectinib
  - Brigatinib
  - Ceritinib
  - Crizotinib
  - Ensartinib
  - Lorlatinib
- **Subsequent therapy**
  - Alectinib
  - Brigatinib
  - Ceritinib
  - Ensartinib
  - Lorlatinib

ROS1 Rearrangement

- **First-line therapy**
  - Crizotinib
  - Entrectinib
  - Repotrectinib
  - Taletrectinib
- **Subsequent therapy**
  - Lorlatinib
  - Entrectinib
  - Repotrectinib
  - Taletrectinib

BRAF V600E Mutation

- **First-line therapy**
  - Dabrafenib/trametinib
  - Encorafenib/binimetinib
  - Dabrafenib
  - Vemurafenib
- **Subsequent therapy**
  - Dabrafenib/trametinib
  - Encorafenib/binimetinib

NTRK1/2/3 Gene Fusion

- **First-line/Subsequent therapy**
  - Larotrectinib
  - Entrectinib
  - Repotrectinib

MET Exon 14 Skipping Mutation

- **First-line/Subsequent therapy**
  - Capmatinib
  - Crizotinib
  - Tepotinib

RET Rearrangement

- **First-line therapy**
  - Selpercatinib
  - Pralsetinib
- **Subsequent therapy**
  - Cabozantinib

HER2 Mutation

- **Subsequent therapy**
  - Fam-trastuzumab deruxtecan-nxki
  - Ado-trastuzumab emtansine

NRG1 Gene Fusion

- **Subsequent therapy**
  - Zenocutuzumab-zbco

HER2-positive IHC 3+

- **Subsequent therapy**
  - Fam-trastuzumab deruxtecan-nxki

C-Met/MET (≥50% IHC 3+ and *EGFR* wild-type)

- **Subsequent therapy**
  - Telisotuzumab vedotin-tllv (nonsquamous)

PD-L1 ≥50% First-Line Therapy
PD-L1 ≥1%-49% First-Line Therapy

Patient Case 1

- Mrs. B, a 77-year-old female with advanced NSCLC
- History of previous tobacco use; recently decreased performance status due to progressing cancer
- Given her age, she proceeds directly with empiric chemotherapy and supportive care

General Consensus on Biomarker Testing in NSCLC

- Guideline consensus from NCCN, ASCO, CAP, SEOM
- Broad molecular profiling is recommended at diagnosis for all patients with advanced or mNSCLC, regardless of clinical characteristics (e.g., histology, age, smoking status)
- Biomarkers to be tested routinely:
  - *EGFR*, *ALK*, *ROS1*, *BRAF*, *NTRK1/2/3*, *MET*, *RET*, *KRAS*, *HER2* mutations/fusions
  - PD-L1 protein expression for immunotherapy eligibility
- NGS methods are encouraged for more comprehensive and efficient assessment
  - Liquid biopsy is increasingly accepted when tissue is insufficient or inaccessible

CAP = College of American Pathologists; mNSCLC = metastatic NSCLC; SEOM = Spanish Society of Medical Oncology.

Gerlach A. Pharmacy Times Website. 2025. https://www.pharmacytimes.com/view/biomarker-testing-transforms-nsclc-care-but-gaps-persist-in-community-settings. Batra U, Nathany S. *Oncol Rev*. 2025;18:1445826. LUNGevity Foundation. No One Missed Website. 2021. https://noonemissed.org/sites/default/files/2025-05/NOM_HCP_Resources_HCP_Fact_Sheet_WEB_Updated_2022.pdf. Roth MJ, et al. *J Clin Oncol*. 2025;43(16_suppl):8541.

Optimizing Biomarker Testing in NSCLC

- Adopt institutional pathways ensuring timely, comprehensive, and guideline-concordant testing for all eligible patients
- Integrate regular educational updates for staff regarding new biomarkers and approved therapies
- Monitor and audit local biomarker testing rates, barriers, and outcomes to identify and address disparities
- Maintain open communication with patients about the value, logistics, and results of biomarker testing

National Comprehensive Cancer Network (NCCN). NCCN Website. 2025. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
Oncology Practice Management (OPM). OPM Website. 2017. https://oncpracticemanagement.com/issues/2017/may-2017-vol-7-no-5/nccn-recommends-biomarker-testing-for-all-patients-with-newly-diagnosed-non-small-cell-lung-cancer.

Biomarker Testing Underutilization in the United States

- 17,165 patients with NSCLC in national EHR database
  - Only 67% of all patients and 77% of patients with nonsquamous mNSCLC had ALK, EGFR, and PD-L1 testing within 90 days of diagnosis
  - Lower rates associated with stage IIIB/C disease (compared to stage IV), squamous histology, and Black or African American race
- MYLUNG: 987 patients, 12 community practices (69 sites)
  - 64% of patients with early-stage NSCLC and 83% of patients with mNSCLC had at least one biomarker result prior to treatment initiation
    - 36% and 17%, respectively, did not have any testing
  - 37% of patients with mNSCLC had results for all nine recommended biomarkers
  - Large-panel NGS testing occurred in 37% and 57% of the early-stage and mNSCLC cohorts, respectively

EHR = electronic health record.

Baron JM, et al. *JCO Precis Oncol.* 2024(8):e2400039.
Evangelist MC, et al. *J Clin Oncol.* 2023;41(16_suppl):9109. https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.9109.

Biomarker Testing Underutilization Globally

- 2024 IASLC Global Survey
  - 1,677 respondents in 90 countries
  - 98% believed that biomarker testing significantly impacted outcomes, though only 63.4% and 29.4% ranked it highly important in late- and early-stage disease, respectively
  - 67% estimated that more than half of individuals with lung cancer are biomarker tested in their country
  - 43% of respondents sometimes/often treat patients prior to receiving biomarker results

IASLC = International Association for the Study of Lung Cancer.

Smeltzer MP, et al. *J Thorac Oncol.* 2025 Jul 22:S1556-0864(25)00937-2. [Epub ahead of print].

NSCLC in Older Patients

- Paucity of clinical trial data with older and very old patients
- Geriatric patients are at risk of organ, marrow, and cognitive dysfunction; polypharmacy; and low functional reserves

- However, the elderly population is heterogeneous, and chronological age alone **does not** reflect the extent of the aging process
  - Geriatric patient management should be mostly determined by functional age
  - Geriatric assessment tools:
    - Comprehensive Geriatric Assessment (CGA)
    - Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH)
    - Cancer Aging Research Group (CARG) scores

At diagnosis:

50%
of patients with NSCLC are age ≥70 and

15%
are age >80

Almodovar T, et al. *Pulmonology.* 2019;25(1):40-50.

Comparison of Targeted Therapies with Platinum-Based Chemotherapy in Geriatric Patients

- Platinum-based therapy has modest efficacy in patients age 70-79 and has good performance status
  - Higher risk of grade ≥3 AEs, including death; hematologic, renal, and neurologic AEs are common
- Targeted therapies are superior in tumors with actionable mutations
  - They are generally better tolerated than cytotoxic chemotherapies but may have unique high-grade AEs at higher frequency
  - Polypharmacy and drug interactions are more common
- Immune checkpoint inhibitors are superior in high PD-L1+ tumors
  - Efficacy diminishes in the very old (age >75)
  - Incidence of immune-related AEs increases in elderly patients

AEs = adverse events.

National Comprehensive Cancer Network (NCCN). NCCN Website. 2025. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
Kim ST, et al. *Cancer Res Treat*. 2012;44(1):37-42. Yao J, et al. *EClinicalMedicine*. 2025;81:103081.

First-Line Immune Checkpoint Inhibitors (ICIs) in Real-Life Elderly Patients with Advanced NSCLC

1,245 Japanese patients age ≥75 with stage IIIB/IIIC/IV NSCLC (Dec. 2018–Mar. 2021)

Treatment Group	Number of Patients (%)	Median OS (months, 95% CI)
ICI-chemotherapy	354 (28%)	20.0 (17.1-23.6)
ICI alone	425 (34%)	19.8 (16.5-23.8)
Platinum-doublet chemotherapy	311 (25%)	12.8 (10.7-15.6)
Single-agent chemotherapy	155 (12%)	9.5 (7.4-13.4)

No difference in OS and PFS between ICI-chemotherapy group (n = 96) and ICI-alone group (n = 95) in PD-L1 ≥1%

PD-L1 Group	Number of Patients (%)
<1%	268 (22%)
1%-49%	387 (31%)
≥50%	410 (34%)

Grade ≥3 irAEs

- 86 patients (24.3%) in the ICI-chemotherapy group
- 76 patients (17.9%) in the ICI-alone group (*P* = .03)

Patients who required steroids for irAEs

- 115 (32.5%) in the ICI-chemotherapy group
- 105 (24.7%) in the ICI-alone group (*P* = .02)

Pneumonitis

- 83 patients (23.4%) in the ICI-chemotherapy group
- 66 patients (15.6%) in the ICI-alone group (*P* = .006)

CI = confidence interval; irAEs = immune-related adverse events; OS = overall survival; PFS = progression-free survival.

Uematsu M, et al. *J Clin Oncol*. 2023;41(16_suppl):9012.

Key Points for Practice for Geriatric Patients

- For patients age >70 with actionable mutations, targeted therapies are preferred due to greater efficacy and better safety/tolerability profiles
- Smoking history should not be an exclusion criteria for biomarker testing
- In mutation-negative and/or frail elderly patients, chemotherapy should be reserved for those with good performance status
- Platinum-based chemotherapy is associated with higher toxicity and smaller survival gain in the very old (age >80), where the benefit may not outweigh risk
- Special attention should be paid to unique toxicities of targeted therapies (e.g., pneumonitis, cardiac, metabolic AEs)

Patient Case 1

Mrs. B's oncologist presumes that “she is too old and frail to benefit from targeted therapy or clinical trials” and proceeds directly with empiric chemotherapy and supportive care. Biomarker testing was not ordered at diagnosis or after disease progression.

- The provider’s age-related bias led to the mistaken belief that older patients cannot tolerate or benefit from targeted therapies, resulting in omission of guideline-recommended biomarker workup
- This practice resulted in Mrs. B missing the chance for a more effective and potentially less toxic therapy and possibly eligibility for novel agents via clinical trials

End of case: Mrs. B had a tumor with a *KRAS* mutation

- While not informative for first-line treatment, it suggests second-line options that may be more tolerable than additional chemotherapy

Patient Case 1

Points for Improvement:

- Mandatory reflex biomarker testing upon diagnosis for every eligible patient, regardless of age or perceived frailty
- Team education emphasizing that age and performance status should not defer testing if systemic therapy is considered
- Involve multidisciplinary care (oncology, geriatrics, molecular pathology) to address and overcome age-related and functional status biases

Social Drivers of Health

Health is determined in part by:

- Access to social and economic opportunities
- Resources and supports available in our homes, schools, neighborhoods, and communities
- Conditions in the environments where people are born, live, work, play, and worship, and age, affect health, functioning, and quality of life



Poverty, culture, and social inequity affect medical conditions

Centers for Disease Control and Prevention (CDC). 2022. https://www.cdc.gov/socialdeterminants/index.htm.
American Association for Cancer Research (AACR). 2022. https://cancerprogressreport.aacr.org/disparities/.
Venkataramany BS, et al. *Am J Clin Oncol*. 2022;45(6):273-278.

Lung Cancer and Poverty

U.S. Lung Cancer Death Rates by County
Age-adjusted annual lung cancer death rate, 2010-2019



Counties in grey had too few deaths to calculate a reliable death rate

Percent of Population Living in Poverty by County
2018



2018 Small Area Income and Poverty Estimates
U.S. Census Bureau

Reddit Website. 2021. https://www.reddit.com/r/dataisbeautiful/comments/pkksrh/oc_us_lung_cancer_death_rates_by_county/.
Centers for Disease Control and Prevention (CDC). 2021. https://www.cdc.gov/dhdsp/maps/sd_poverty.htm.

Patient Case 2



- Mr. L, a 60-year-old Black male with newly metastatic nonsquamous NSCLC
- He receives disability income and has Medicaid insurance
- Due to cost and travel constraints and likely limited reimbursement of testing by insurance, single-gene testing for *EGFR*, *ALK*, and *ROS* alterations is performed
- Testing results are negative, and immunotherapy is started

SDOH and Biomarker Testing

- Socioeconomic Status
- Racial and Ethnic Disparities
- Geographic Access: Rural vs Urban
- Health Insurance and Economic Stability
- Education, Health Literacy, and Social Support

SDOH = social determinants of health.

SDOH and Biomarker Testing

Socioeconomic Status

- Lower SES is consistently linked with reduced rates of both traditional and molecular biomarker testing in NSCLC; this includes challenges in affording care, limited health literacy, and lack of awareness about biomarker testing and available treatments
- Patients with lower income or on Medicaid are significantly less likely to receive recommended biomarker panels, even when they have actionable mutations that could improve their prognosis or access to clinical trials

SES = socioeconomic status.

Redondo-Sánchez D, et al. *Cancers (Basel)*. 2022;14(2):398. Kurzrock R, et al. *Cancer Metastasis Rev*. 2024;43(4):1217-1231.
Association of Cancer Care Centers Website. 2025. https://www.accc-cancer.org/home/learn/precision-medicine/cancer-diagnostics/biomarkers/improving-access-to-biomarker-testing-in-medicaid-populations.

SDOH and Biomarker Testing

Racial and Ethnic Disparities

- Black, Hispanic/Latino, and American Indian/Alaska Native patients experience lower rates of biomarker testing and targeted therapy use compared to White patients, even when controlling for insurance status
- Disparities stem from a complex interplay of historical mistrust of the healthcare system, lower referral rates by clinicians, language barriers, and cultural factors

Redondo-Sánchez D, et al. *Cancers (Basel)*. 2022;14(2):398. Kurzrock R, et al. *Cancer Metastasis Rev*. 2024;43(4):1217-1231. Nesline MK, et al. *J Clin Oncol*. 2024;42(16_suppl):e13545-e13545.

SDOH and Biomarker Testing

Geographic Access: Rural vs Urban

- Rural patients are less likely to have access to comprehensive genomic testing and large-panel assays compared to those in urban settings, primarily due to a lack of high-resource laboratories or specialized health care professionals and longer travel distances to cancer centers
- Geographic remoteness also decreases the likelihood of participation in biomarker-driven clinical research

Redondo-Sánchez D, et al. *Cancers (Basel)*. 2022;14(2):398. Kurzrock R, et al. *Cancer Metastasis Rev*. 2024;43(4):1217-1231.
Zhao Y, et al. *Cancer Res Commun*. 2024;4(2):303-311.

SDOH and Biomarker Testing

Health Insurance and Economic Stability

- Uninsured or underinsured patients are less likely to undergo the full range of recommended molecular profiling, even among those with insurance (primarily Medicare)
- Transportation barriers and inability to take time off work (more common among those with economic insecurity) directly impede appointments for biomarker testing or follow-up

Redondo-Sánchez D, et al. *Cancers (Basel)*. 2022;14(2):398. Kurzrock R, et al. *Cancer Metastasis Rev*. 2024;43(4):1217-1231. Nesline MK, et al. *J Clin Oncol*. 2024;42(16_suppl):e13545-e13545.

SDOH and Biomarker Testing

Education, Health Literacy, and Social Support

- Patients with lower educational attainment frequently report less understanding of the importance of testing and are less likely to advocate for comprehensive assessments or to participate in shared decision-making
- Lack of social connections and health advocacy also correlates with lower rates of biomarker testing and poorer survival in NSCLC

Redondo-Sánchez D, et al. *Cancers (Basel)*. 2022;14(2):398. Kurzrock R, et al. *Cancer Metastasis Rev*. 2024;43(4):1217-1231. Nesline MK, et al. *J Clin Oncol*. 2024;42(16_suppl):e13545-e13545.

Patient Case 2



Due to implicit bias and false assumptions about limited access to expensive therapies (“he may not be able to access targeted drugs or clinical trials” and “testing may be denied by insurance”), the provider delays ordering comprehensive molecular profiling for Mr. L. Single-gene *EGFR*, *ALK*, and *ROS* testing results are negative, and immunotherapy is started.

- Implicit bias based on socioeconomic status and ethnicity can significantly lower access to broad, guideline-recommended biomarker panels
- Limited initial testing may miss potentially actionable, rarer mutations, depriving the patient of more effective therapies and clinical trial options

End of case: Mr. L had a HER2+ tumor

- As a result, he received the wrong first-line treatment
- Mr. L experienced rapid disease progression

Patient Case 2



Points for Improvement:

- Implement reflex, panel-based biomarker testing for all patients with NSCLC, regardless of race, insurance, or socioeconomic status
- Educate clinicians and staff on health care disparities and guideline consensus that supports broad molecular testing for every patient
- Build standardized institutional workflows, ensuring that no personal, demographic, or financial bias influences the ordering of comprehensive biomarker profiling

Goals for Increasing Interprofessional Communication and Collaboration



HCPs = health care professionals.

Evans S, et al. *J Interprof Care*. 2025 Feb 6:1-9. [Epub ahead of print]. Bowman KS, et al. *Behav Anal Pract*. 2021;14(4):1191-1208. Price JR, et al. *Sch Psychol*. 2024;39(4):419-432.

Put information into action!

Takeaways from this program can be implemented into your practice to improve patient care.

- *Implement reflex testing protocols* to ensure that all eligible patients, regardless of smoking history or age, receive comprehensive biomarker panels, removing the need for patient/provider initiation
- *Ensure that every patient with NSCLC eligible for systemic therapy is not denied comprehensive biomarker testing* due to misconceptions or operational barriers
- *Promote a team-based approach* to ensure testing is performed early and that results are available to inform therapy choice

CME OUTFITTERS

Visit the

Health Access & Social Responsibility Hub

Free resources and education for health care professionals and patients

https://www.cmeoutfitters.com/practice/diversity-and-inclusion-hub/

CMEO BriefCase

Other program in this series:

Advancing Health Equity Across the Spectrum

Weight of Inequity – Addressing Social and Structural Barriers in Bariatric Surgery

To Receive Credit

To receive CME/CE credit for this activity, participants must complete the post-test and evaluation online.

Participants will be able to download and print their certificate immediately upon completion.

CMEO
BriefCase

Advancing Health Equity Across the Spectrum

Optimizing Biomarker Usage in NSCLC

Supported by an educational grant provided by Johnson & Johnson.